{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005102","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.603924+00:00","generated_at":"2026-06-12T02:07:03.367551+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corvus reports Q2 net loss $6.5M, soquelitinib shows 3 CR/3 PR in TCL; plans FDA meeting","bullets":["Soquelitinib Phase 1/1b: 3 complete, 3 partial responses in 20 evaluable TCL patients.","ALC >900/mL: 6/14 objective responses; 0/6 below 900. FDA meeting for Phase 3 in Q3.","Cash $37.0M as of June 30, 2023; projected $28-30M year-end, funding into H2 2024.","Q2 R&D expense $4.0M (down from $4.9M); net loss $6.5M vs $8.4M in Q2 2022.","Ciforadenant Phase 1b/2 in RCC initial data expected year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005102","json":"https://secwatch.observer/filing/0001171843-23-005102.json","markdown":"https://secwatch.observer/filing/0001171843-23-005102.md","text":"https://secwatch.observer/filing/0001171843-23-005102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/0001171843-23-005102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/f8k_080823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:07:03.367551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"047220198c7f83deb68d859eaf90c2a151d0fe3e","claim":"Corvus Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/0001171843-23-005102-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}